Tempus AI Stock 2025 Latest Price, Growth Outlook, and Investment Insights for TEM

On: April 17, 2025 1:54 AM

Tempus AI Stock: Explore Tempus AI (TEM) stock’s 2025 performance, live share price, and growth outlook. Learn about Tempus AI’s innovations in healthcare, recent financials, analyst ratings, and how to invest in TEM from India or globally. Stay updated on the future of AI-driven healthcare stocks

Tempus AI Stock (TEM) in 2025: Growth, Volatility, and the Future of Healthcare AI

#Tempus AI (NASDAQ: TEM) is making waves in the healthcare technology sector, leveraging artificial intelligence to revolutionize precision medicine and patient care. If you’re considering investing in Tempus AI stock or just want to understand why it’s attracting so much attention in 2025, this blog post breaks down the latest trends, forecasts, and what makes Tempus AI a standout in the AI-driven healthcare space.

What Does Tempus AI Do?

Tempus AI specializes in using artificial intelligence to analyze clinical and molecular data, helping doctors make more informed decisions and deliver personalized treatments. Its business model combines three main segments:

Genomics: High-throughput sequencing and AI-powered diagnostics, especially in oncology.
Data & Services: Licensing de-identified clinical and molecular data to pharmaceutical and biotech companies for research and drug development.
Apps: AI-driven tools for physicians and patients, including clinical trial matching and personalized health insights8.

Recent acquisitions, like Ambry Genetics and Deep 6 AI, have expanded Tempus’s capabilities in genomics and clinical trial recruitment, strengthening its position as a leader in healthcare AI8.

Tempus AI Stock Performance in 2025

Current Price (April 2025): Around $41–$43 per share1 9
52-Week Range: $22.89 – $91.4511
Market Cap: ~$7.8 billion11
2025 Revenue Guidance: $1.24 billion (up 79% year-over-year)4 6
Adjusted EBITDA (2025): Projected at $5 million, a major improvement over 20244 6

Recent Trends:

The stock surged nearly 40% year-to-date as of March 2025, outperforming the broader medical and tech sectors2 3.
After a strong rally, shares experienced volatility following a Q4 2024 earnings miss and cautious 2025 guidance, but have since rebounded on news of strategic acquisitions and partnerships2 7.
Institutional investors have shown strong interest, with over 65% of the float held by institutions11 13.

Analyst Ratings and Price Targets

Analyst Firm	Rating	Price Target ($)
Morgan Stanley	Buy	$60
TD Cowen	Buy	$74
Loop Capital	Buy	$52
Needham	Buy	$56
Wolfe Research	Outperform	$60
JP Morgan	Neutral	$55
BofA Securities	Neutral	$54
Guggenheim	Buy	$74

Average 12-Month Target: $61.18 (range: $48–$74)12 10
2025 Share Price Forecast: Most experts expect a range of $50–$70 by year-end, with bullish scenarios reaching $7411 12.

Growth Drivers for Tempus AI

AI-Powered Diagnostics: Tempus’s AI tools are gaining traction in oncology, cardiology, and mental health, driving higher test volumes and data licensing revenue8.
Strategic Acquisitions: The addition of Ambry Genetics and Deep 6 AI expands Tempus’s reach in genomics and clinical trials, opening new revenue streams8.
Strong Partnerships: Renewed multi-year deals with Google and major pharmaceutical companies support Tempus’s data and AI infrastructure6 8.
Market Leadership: Tempus’s proprietary multimodal dataset and high client retention (140%) create high entry barriers for competitors5 8.

Risks and Volatility

Stock Volatility: Shares have been highly volatile, with sharp drops after earnings misses and market corrections7 13.
Short Interest: High short interest (up to 25%) has contributed to price swings13.
Profitability Timeline: While revenue is growing rapidly, consistent profitability is expected by 202613.
Bearish Sentiment: Some technical indicators and forecasts suggest short-term downside risk, with a bearish sentiment and a price prediction as low as $28.83 by May 20259.

Is Tempus AI Stock a Good Buy in 2025?

Pros:

Leading position in healthcare AI and precision medicine
Rapid revenue growth and expanding market share
Strong institutional backing and strategic partnerships
High client retention and recurring revenue

Cons:

High volatility and short-term uncertainty
Not yet consistently profitable
Competitive and regulatory risks in healthcare and AI

Expert Consensus: Most analysts rate Tempus AI as a “Moderate Buy” for long-term investors who can handle volatility and are bullish on the future of AI in healthcare12 13.

Conclusion

Tempus AI is at the forefront of the healthcare AI revolution, with a unique business model that combines genomics, data, and AI-driven applications. While the stock is volatile and faces short-term risks, its long-term growth prospects remain strong thanks to rapid revenue growth, strategic acquisitions, and a growing role in precision medicine. For investors seeking exposure to the future of healthcare technology, Tempus AI is a stock worth watching in 2025 and beyond.